October 19, 2005
ASA Files
Comments on FDA Propofol Petition
ASA's letter urges
FDA to retain the warning label limiting the use
of propofol to clinicians trained in the administration
of general anesthesia and not involved in the conduct
of the surgical/diagnostic procedure.
Instructions for submitting your own
comments.
ASA
LETTER TO FDA 
ATTACHMENT
1 - STATEMENT ON SAFE USE OF PROPOFOL 
ATTACHMENT
2 - PRACTICE GUIDELINES FOR SEDATION AND ANALGESIA
BY NON-ANESTHESIOLOGISTS 
ASA
ANALYSIS - PROPOFOL BY NON-ANESTHESIOLOGISTS
(EXCEL
FILE)
SUBMITTING COMMENTS TO FDA ON PROPOFOL LABELING
The FDA will continue to accept comments until December
27, 2005. You may submit comments either by mail to:
Division of Dockets Management (HFA-305)
Food and Drug Administration
5630 Fishers Lane, Room 1061
Rockville, MD 20852
Be sure to include the Docket Number 2005P-0267
or submit electronically on the FDA's
website.
Key points you might make include (illustrate
with examples from your own experience, if possible):